TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31734334

Group type: EXPERIMENTAL
Intervention: Twice-daily GSP301 (olopatadine 665 μg and mometasone 25 μg)
Number of subjects: 1111

Group type: EXPERIMENTAL
Intervention: Once-daily GSP301 (olopatadine 665 μg and mometasone 50 μg)
Number of subjects: 1111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1111

Group type: EXPERIMENTAL
Intervention: Twice-daily olopatadine (665 μg)
Number of subjects: 1111

Group type: EXPERIMENTAL
Intervention: Mometasone monotherapy (twice-daily 25 μg or once-daily 50 μg)
Number of subjects: 1111

Group type: EXPERIMENTAL
Intervention: Twice-daily mometasone
Number of subjects: 1111
Study: 30528849

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (carbohydrates, proteins, electrolytes, osmolarity of 680 mO.L‐1, 300 kcal)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Isotonic solution (carbohydrates, electrolytes, osmolarity of 292 mOsm.L‐1, 36 kcal)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Fasting (control group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Comparison between isotonic solution and nutritional supplementation
Number of subjects: 34
Study: 30067065

Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Rope skipping
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Number of subjects: 63

Group type: COMPARATOR
Intervention: Older population (40-55 years) vs. younger population (18-25 years)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Older male participants vs. older female participants
Number of subjects: 63
Study: 27608621

Group type: EXPERIMENTAL
Intervention: Mindfulness-based lifestyle program (6-week duration)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 35
Study: 24507377

Group type: EXPERIMENTAL
Intervention: EMA401 (100 mg twice daily)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 22126134

Group type: EXPERIMENTAL
Intervention: Randomized presentation of immediate rewards
Number of subjects: 9454

Group type: EXPERIMENTAL
Intervention: Ascending presentation of immediate rewards
Number of subjects: 9454

Group type: EXPERIMENTAL
Intervention: Descending presentation of immediate rewards
Number of subjects: 9454

Group type: EXPERIMENTAL
Intervention: Delays between 1 week and 5 years with delayed amounts of $1000 and $100 for 1 month
Number of subjects: 9454

Group type: EXPERIMENTAL
Intervention: Hyperbolic DRD function
Number of subjects: 9454

Group type: EXPERIMENTAL
Intervention: Methodology variations (randomized order, longer delays, smaller rewards)
Number of subjects: 9454
Study: 19443189

Group type: EXPERIMENTAL
Intervention: Active treatment with purified air
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo treatment with unfiltered air
Number of subjects: 22
Study: 17192489

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg/day) and Fenofibrate (160 mg/day)
Number of subjects: 8
Study: 15113785

Group type: EXPERIMENTAL
Intervention: Regular feedback to primary care providers of synthesized information on patients' health, function, and satisfaction.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control firms (no feedback provided).
Number of subjects: 0
Study: 11245863

Group type: EXPERIMENTAL
Intervention: Home care management (EG)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Hospital care management (CG)
Number of subjects: 250
Study: 9555866

Group type: EXPERIMENTAL
Intervention: Fat-rich breakfast with palmitic acid (21.7 g)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Fat-rich breakfast with stearic acid (18.6 g)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Fat-rich breakfast with linoleic/linolenic acid (ratio 3:1)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Fat-rich breakfast with linoleic/linolenic acid (ratio 15:1)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control breakfast (1.5 en% fat)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Fat-rich breakfasts (all types)
Number of subjects: 91
Study: 8053586

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (target temperature 35 degrees C, allowed to drift to 34.5 degrees C before rewarming)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normothermia (target temperature 36.5-37.0 degrees C)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Number of subjects: 30
Study: 3419245

Group type: EXPERIMENTAL
Intervention: Atropine (1 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atropine (2 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pirenzepine (20 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atropine (1 mg and 2 mg)
Number of subjects: 8
Study: 29354936

Group type: EXPERIMENTAL
Intervention: Aconite cake-separated moxibustion
Number of subjects: 90

Group type: COMPARATOR
Intervention: Moxibustion
Number of subjects: 90

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 90
Study: 26597705

Group type: EXPERIMENTAL
Intervention: PGA-FS
Number of subjects: 786

Group type: COMPARATOR
Intervention: CF
Number of subjects: 786
Study: 25273077

Group type: COMPARATOR
Intervention: S-1
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: S-1 in combination with leucovorin (SL)
Number of subjects: 92
Study: 22207279

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 68
Study: 20228415

Group type: EXPERIMENTAL
Intervention: 5-lipoxygenase inhibitor
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 18028881

Group type: EXPERIMENTAL
Intervention: riluzole
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (untreated volunteers)
Number of subjects: 14
Study: 15681102

Group type: EXPERIMENTAL
Intervention: Early postoperative enteral immunonutrition (formula supplemented with arginine, omega‐3 fatty acids and RNA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Isocaloric‐isonitrogenous control formula
Number of subjects: 66
Study: 12658934

Group type: EXPERIMENTAL
Intervention: Continuous spinal anesthesia (CSA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combined spinal-epidural anesthesia (CSEA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CSEA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CSA
Number of subjects: 60
Study: 8841865

Group type: EXPERIMENTAL
Intervention: Bupivacaine with epinephrine (5 micrograms/mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plain bupivacaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Bupivacaine with and without epinephrine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bupivacaine with epinephrine
Number of subjects: 40
Study: 2253572

Group type: EXPERIMENTAL
Intervention: WHO‐MDT
Number of subjects: 127

Group type: COMPARATOR
Intervention: Modified‐MDT
Number of subjects: 127
Study: 6254457

Group type: EXPERIMENTAL
Intervention: Vidarabine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30601161

Group type: EXPERIMENTAL
Intervention: Angiotensin II (Giapreza)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27180065

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Body fat percentage (BF%)
Number of subjects: 84
Study: 26062189

Group type: EXPERIMENTAL
Intervention: Flurphen mixture (droperidol injection 1.25 mg and fentanyl citrate injection 0.05 mg diluted to 6 mL with 0.9% sodium chloride solution 4.5 mL) injected at bilateral Shenshu (BL 23) 15 to 20 min before ESWL.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group with no adjuvant therapy or medication before ESWL.
Number of subjects: 64
Study: 23199451

Group type: EXPERIMENTAL
Intervention: Highest quartile of change in white bread intake
Number of subjects: 2213
Study: 22151934

Group type: EXPERIMENTAL
Intervention: L‐ascorbic acid 10% + phytic acid 2%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 30
Study: 19430833

Group type: EXPERIMENTAL
Intervention: Adrenaline injection (1:10,000)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Endoloop and hemoclip application
Number of subjects: 64
Study: 17561127

Group type: EXPERIMENTAL
Intervention: Intraprostatic local anesthesia with 2 ml 1% lidocaine and periprostatic injection of 2 ml saline (Group 1)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Intraprostatic injection of 2 ml saline followed by periprostatic local anesthesia with 2 ml 1% lidocaine (Group 2)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Intraprostatic and periprostatic local anesthesia with 2 ml 1% lidocaine (Group 3)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (saline injection)
Number of subjects: 152
Study: 15334503

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis children with meconium ileus (MI)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cystic fibrosis children without meconium ileus (control group)
Number of subjects: 32
Study: 11158797

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% (n = 127)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Fixed-combination latanoprost 0.005%-timolol 0.5% (FC, n = 116)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Timolol 0.5% (n = 126)
Number of subjects: 369
Study: 10495194

Group type: EXPERIMENTAL
Intervention: Hypothetical psychotherapy data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational study data
Number of subjects: 0
Study: 7481176

Group type: EXPERIMENTAL
Intervention: Previously diagnosed diabetes
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Previously undiagnosed diabetes
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Undiagnosed diabetes
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Marked obesity (BMI 30 kg/m2 or more)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Previously diagnosed diabetic patients
Number of subjects: 1008
Study: 1973905

Group type: EXPERIMENTAL
Intervention: 10 mg oral dose of gepirone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 10 mg gepirone (acute administration)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Chronic administration of gepirone (3-6 weeks)
Number of subjects: 14
Study: 13090

Group type: EXPERIMENTAL
Intervention: Anisotropine methylbromide (high doses)
Number of subjects: 0
Study: 31278508

Group type: EXPERIMENTAL
Intervention: Joline RapidIntro Vertebra Access Device with a trocar tip
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Joline SpeedTrack Vertebra Introducer Device with a short, tapered tip
Number of subjects: 65

Group type: COMPARATOR
Intervention: Joline Vertebra Access Device (control)
Number of subjects: 65
Study: 28794060

Group type: EXPERIMENTAL
Intervention: Multidisciplinary community-based obesity programme
Number of subjects: 233
Study: 25912051

Group type: EXPERIMENTAL
Intervention: Intravenous carbamazepine (IV) administered as multiple 30- or 15-min infusions every 6 h, and as a single rapid infusion
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Intravenous carbamazepine (IV) administered as rapid infusions
Number of subjects: 203

Group type: COMPARATOR
Intervention: Oral carbamazepine
Number of subjects: 203
Study: 24018675

Group type: EXPERIMENTAL
Intervention: Sparassis crispa (SC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21846343

Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not given omega-3 supplements)
Number of subjects: 0
Study: 19214137

Group type: EXPERIMENTAL
Intervention: IL‐10 (8 microg/kg)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: IL‐10 (20 microg/kg)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 17437662

Group type: EXPERIMENTAL
Intervention: Biochemical markers of type II collagen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunoassays detecting fragments of aggrecan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of different biochemical markers
Number of subjects: 0
Study: 15156527

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ARBs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual ACE inhibitor-ARB therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE inhibitors and ARBs (combined)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE inhibitors (from trials)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ARBs (from trials)
Number of subjects: 0
Study: 11699048

Group type: EXPERIMENTAL
Intervention: FABP2 Thr/Thr genotype in older normoglycemic men
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: beta3AR Arg64-positive subjects in older normoglycemic men
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: beta3AR Arg64-positive group in older hyperglycemic men
Number of subjects: 504
Study: 9542852

Group type: EXPERIMENTAL
Intervention: 1-minute scrub with povidone-iodine followed by alcohol foam
Number of subjects: 37

Group type: COMPARATOR
Intervention: 5-minute scrub with povidone-iodine
Number of subjects: 37
Study: 10168562

Group type: EXPERIMENTAL
Intervention: Excel cell separator
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: MCS 3p cell separator
Number of subjects: 25

Group type: COMPARATOR
Intervention: CS3000 plus, AS 104, Cobe Spectra
Number of subjects: 25
Study: 2689236

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 115

Group type: COMPARATOR
Intervention: Radiotherapy with short-term (ST) 5-FU (575 mg/m2 daily for 4 days before irradiation)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Radiotherapy with long-term (LT) 5-FU (750 mg/m2 every 2 weeks for 18 months)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Radiotherapy with both ST and LT 5-FU
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with ST and LT 5-FU
Number of subjects: 115
Study: 30974973

Group type: EXPERIMENTAL
Intervention: Insulin degludec (degludec) using FlexTouch1
Number of subjects: 145
Study: 28152999

Group type: EXPERIMENTAL
Intervention: Participatory supportive return to work program
Number of subjects: 186

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 186
Study: 26248094

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 23760870

Group type: EXPERIMENTAL
Intervention: Imidacloprid 10 %/flumethrin 4.5 % polymer matrix collar (Seresto®, Bayer)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo collar
Number of subjects: 16
Study: 21630126

Group type: EXPERIMENTAL
Intervention: Incidence of diabetic retinopathy
Number of subjects: 1211

Group type: EXPERIMENTAL
Intervention: Progression of diabetic retinopathy
Number of subjects: 1211

Group type: EXPERIMENTAL
Intervention: HbA(1c) associated with incident diabetic retinopathy
Number of subjects: 1211

Group type: EXPERIMENTAL
Intervention: Duration of diabetes associated with incident diabetic retinopathy
Number of subjects: 1211

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure associated with incident diabetic retinopathy
Number of subjects: 1211

Group type: EXPERIMENTAL
Intervention: Body mass index associated with incident diabetic retinopathy
Number of subjects: 1211

Group type: EXPERIMENTAL
Intervention: HbA(1c) associated with progression of diabetic retinopathy
Number of subjects: 1211
Study: 19509350

Group type: EXPERIMENTAL
Intervention: Sildenafil treatment
Number of subjects: 0
Study: 16512939

Group type: EXPERIMENTAL
Intervention: Algal oil containing 1.5 g DHA and 0.6 g DPA, 4 g oil/d for 4 weeks
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 15165387

Group type: EXPERIMENTAL
Intervention: RICE method plus an 820‐nm GaA1As diode laser with a radiant power output of 40 mW at 16 Hz
Number of subjects: 47

Group type: COMPARATOR
Intervention: RICE method plus placebo laser
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional initial treatment (RICE, rest, ice, compression, elevation)
Number of subjects: 47
Study: 11167172

Group type: EXPERIMENTAL
Intervention: Propofol infusion (100 microg kg(‐1) min(‐1))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sevoflurane (1.0%, end‐tidal) with nitrous oxide 66%
Number of subjects: 0
Study: 9263157

Group type: EXPERIMENTAL
Intervention: Topical application of 30 mg ketoprofen plaster once daily for 5 days (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single oral dose of 50 mg ketoprofen (n = 30)
Number of subjects: 60
Study: 8390329

Group type: EXPERIMENTAL
Intervention: lidocaine 2% with adrenaline 1:200,000 plus 0.1 mEq.ml‐1 sodium bicarbonate
Number of subjects: 116

Group type: COMPARATOR
Intervention: lidocaine 2% with adrenaline 1:200,000 without sodium bicarbonate
Number of subjects: 116
Study: 3655305

Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 29498480

Group type: EXPERIMENTAL
Intervention: Diclometh 0.2%
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Diclometh 0.1%
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Diclometh 0.2% and Diclometh 0.1%
Number of subjects: 21
Study: 28817132

Group type: EXPERIMENTAL
Intervention: Plasma of argon treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cleaning protocol by steam (Control)
Number of subjects: 20
Study: 25737017

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study: 24040851

Group type: EXPERIMENTAL
Intervention: Nalfurafine 5 μg intravenously after each hemodialysis session
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (81 ESRD patients without uremic pruritus)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Nalfurafine and Control group
Number of subjects: 146
Study: 21385240

Group type: EXPERIMENTAL
Intervention: Clinical medication review by community pharmacists
Number of subjects: 498

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 498
Study: 19194354

Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard lymphadenectomy
Number of subjects: 0
Study: 16136309

Group type: EXPERIMENTAL
Intervention: monoHER (100 mg/m2 to 1,500 mg/m2, administered as an i.v. infusion in 10 min)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (100 ml dextrose 5%)
Number of subjects: 9
Study: 12933531

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Hormone therapy (HT) with micronized progesterone (MP, 100 mg) and conjugated equine estrogen (CEE, 0.625 mg)
Number of subjects: 53
Study: 11086281

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg tablets) taken daily for three months, during or outside meals
Number of subjects: 3223

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg tablets)
Number of subjects: 3223
Study: 9542771

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (25 grams of creatine monohydrate daily for three days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 12
Study: 8268595

Group type: EXPERIMENTAL
Intervention: FUT-175 (2 mg/kg/hr)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (sodium heparin 3 mg/kg)
Number of subjects: 25
Study: 3855337

Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 0
Study: 30223046

Group type: EXPERIMENTAL
Intervention: High-velocity circuit resistance training (HVCRT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Steady-state, moderate-intensity treadmill training (TM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 30
Study: 27020109

Group type: EXPERIMENTAL
Intervention: Experimental treatment plans
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard treatment plans
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard and experimental arms
Number of subjects: 35
Study: 24935755

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) with smoking abstinence-contingent incentives (expired CO < 6 ppm; urinary cotinine < 30 ng/ml) for 4 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Monitoring with behavioral support
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 45
Study: 23227687

Group type: COMPARATOR
Intervention: Single-needle group (1 silver needle, 18 cm length, 1.1 mm diameter)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Multi-needle group (1 silver needle + 4 additional needles, 2 cm apart)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Single-needle group (1 silver needle)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Multi-needle group (1 silver needle + 4 additional needles)
Number of subjects: 36
Study: 20706150

Group type: EXPERIMENTAL
Intervention: Esomeprazole 5 or 10 mg once daily
Number of subjects: 31
Study: 18931203

Group type: EXPERIMENTAL
Intervention: Cell salvage
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control
Number of subjects: 213
Study: 15975487

Group type: EXPERIMENTAL
Intervention: Immune-enhancing formula (n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional early enteral nutrition (n=25)
Number of subjects: 50
Study: 12451199

Group type: EXPERIMENTAL
Intervention: CPI-1189 100 mg/day
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: CPI-1189 50 mg/day
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: CPI-1189
Number of subjects: 64
Study: 10359461

Group type: EXPERIMENTAL
Intervention: Individual drug counseling plus group drug counseling (GDC)
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Individual drug counseling plus GDC
Number of subjects: 487

Group type: COMPARATOR
Intervention: GDC alone
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus GDC
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Supportive‐expressive therapy plus GDC
Number of subjects: 487